Bactiguard: Leaving a tough quarter behind - SEB

The Q2 report showed that Covid-19 is still challenging for Bactiguard, although it showed signs of stabilisation in BD licence revenues. Based on a continued roll-out of vaccines and gradually returning general healthcare, we expect improving sales of BIP products in H2. In addition, Bactiguard’s ability to reach licence deals across further product categories should improve with better budgets among partners and less focus on the pandemic.

https://research.sebgroup.com/corporate/reports/109433